Design, Structure–Activity Relationship, and in Vivo Characterization of the Development Candidate NVP-HSP990

Christopher M. McBride(Novartis (Switzerland)), Cynthia M. Shafer(Novartis (Switzerland)), Brandon Doughan, Kristin M. Brinner, Pietro Taverna, Zhenhai Gao(Jilin University), Daniel Poon(Rapt Therapeutics (United States)), Daniel L. Menezes(Bristol-Myers Squibb (Germany)), Kris Mendenhall, Nancy Pryer(Novartis (United States)), Timothy Machajewski(Allogene Therapeutics (United States)), Yongjin Xu, Dachuan Lei, Barry H. Levine(Novartis (Switzerland)), Alice Rico, Julie Qiaojin Lin(University of Hong Kong), William Antonios-McCrea(Novartis (Switzerland)), Yi Xia, Paul A. Barsanti, Susan Fong, Teresa E. Williams(Novartis (Switzerland)), Cornelia Bellamacina, Alicia K. Louie(Novartis (Switzerland)), Tinya J. Abrams, Yasheen Zhou, Thomas F. Hendrickson, Xiaodong Lin(Wenzhou City People's Hospital), Abran Costales(Novartis (Switzerland)), Michael Wang, Maureen McKenna(Novartis (Switzerland)), Paul A. Renhowe(Novartis (Switzerland))
Journal of Medicinal Chemistry
November 4, 2014
Cited by 28


Related Papers